A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 Melanoma
Completed · Phase 3
Conditions studied: Metastatic Melanoma
In brief
To compare the safety and efficacy of Allovectin-7® versus Dacarbazine (DTIC)or Temozolomide (TMZ) in subjects with recurrent stage 3 or stage 4 melanoma.
Key facts
- Study ID
- NCT00395070
- Run by
- Vical
- People needed
- 390
- Starts
- 2006-10-01
- Expected to finish
- 2013-07-01
- Last updated by the study team
- 2013-09-13
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Location #9 — Little Rock, Arkansas, United States
- Location #1 — Bakersfield, California, United States
- Location #24 — San Diego, California, United States
- Location #36 — San Diego, California, United States
- Location #47 — San Francisco, California, United States
- Location #16 — Denver, Colorado, United States
- Location #11 — Lakeland, Florida, United States
- Location #7 — Chicago, Illinois, United States
- Location #33 — Chicago, Illinois, United States
- Location #20 — Louisville, Kentucky, United States
- Location #35 — Baltimore, Maryland, United States
- Location #4 — Kansas City, Missouri, United States
- Location #19 — St Louis, Missouri, United States
- Location #38 — Hackensack, New Jersey, United States
- Location #8 — Montclair, New Jersey, United States
- Location #87 — Albuquerque, New Mexico, United States
- Location #41 — Cincinnati, Ohio, United States
- Location #23 — Cleveland, Ohio, United States
- Location #34 — Portland, Oregon, United States
- Location #12 — Bethlehem, Pennsylvania, United States
- Location #97 — Providence, Rhode Island, United States
- Location #28 — Dallas, Texas, United States
- Location #117 — Houston, Texas, United States
- Location #27 — Salt Lake City, Utah, United States
- Location #40 — Tucson, Arizona, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.